Get Cash Back and $0 Commissions + The Power of TradeStation
Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals Discovering Underlying Factors of Influence
Globe Newswire 11-Oct-2018 9:00 AM
NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Materion Corporation (NYSE:MTRN), Iridium Communications Inc (NASDAQ:IRDM), Natural Health Trends Corp. (NASDAQ:NHTC), Revance Therapeutics, Inc. (NASDAQ:RVNC), Baxter International Inc. (NYSE:BAX), and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine Materion Corporation (NYSE:MTRN), Iridium Communications Inc (NASDAQ:IRDM), Natural Health Trends Corp. (NASDAQ:NHTC), Revance Therapeutics, Inc. (NASDAQ:RVNC), Baxter International Inc. (NYSE:BAX), and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 9th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
MATERION CORPORATION (MTRN) REPORT OVERVIEW
Materion's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Materion reported revenue of $309.09MM vs $295.84MM (up 4.48%) and analysts estimated basic earnings per share $0.55 vs $0.37 (up 48.65%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Materion reported revenue of $1,139.45MM vs $969.24MM (up 17.56%) and analysts estimated basic earnings per share $0.57 vs $1.29 (down 55.81%). Analysts expect earnings to be released on October 25th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.50. The estimated EPS forecast for the next fiscal year is $2.46 and is expected to report on February 21st, 2019.
For the three months ended June 30th, 2018 vs June 30th, 2017, Iridium Communications reported revenue of $134.93MM vs $111.60MM (up 20.90%) and analysts estimated basic earnings per share -$0.06 vs $0.21. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Iridium Communications reported revenue of $448.05MM vs $433.64MM (up 3.32%) and analysts estimated basic earnings per share $2.23 vs $1.00 (up 123.00%). Analysts expect earnings to be released on October 25th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.23. The estimated EPS forecast for the next fiscal year is -$0.37 and is expected to report on February 28th, 2019.
NATURAL HEALTH TRENDS CORP. (NHTC) REPORT OVERVIEW
Natural Health Trends' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Natural Health Trends reported revenue of $50.91MM vs $51.47MM (down 1.08%) and analysts estimated basic earnings per share $0.80 vs $0.92 (down 13.04%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Natural Health Trends reported revenue of $197.56MM vs $287.73MM (down 31.34%) and analysts estimated basic earnings per share $2.10 vs $4.84 (down 56.61%). Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018.
For the three months ended June 30th, 2018 vs June 30th, 2017, Revance Therapeutics reported revenue of $0.69MM vs $0.08MM (up 814.67%) and basic earnings per share -$0.94 vs -$0.90. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Revance Therapeutics reported revenue of $0.26MM vs $0.30MM (down 12.67%) and analysts estimated basic earnings per share -$4.01 vs -$3.18. Analysts expect earnings to be released on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$1.01. The estimated EPS forecast for the next fiscal year is -$3.99 and is expected to report on February 27th, 2019.
For the three months ended June 30th, 2018 vs June 30th, 2017, Baxter International reported revenue of $2,842.00MM vs $2,605.00MM (up 9.10%) and analysts estimated basic earnings per share $0.64 vs $0.49 (up 30.61%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Baxter International reported revenue of $10,561.00MM vs $10,163.00MM (up 3.92%) and analysts estimated basic earnings per share $1.32 vs $9.09 (down 85.48%). Analysts expect earnings to be released on October 31st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.64. The estimated EPS forecast for the next fiscal year is $3.29 and is expected to report on February 7th, 2019.
For the three months ended June 30th, 2018 vs June 30th, 2017, Alexion Pharmaceuticals reported revenue of $1,045.00MM vs $912.70MM (up 14.50%) and analysts estimated basic earnings per share -$2.05 vs $0.74. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Alexion Pharmaceuticals reported revenue of $3,551.10MM vs $3,084.10MM (up 15.14%) and analysts estimated basic earnings per share $1.98 vs $1.78 (up 11.24%). Analysts expect earnings to be released on October 24th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $1.28. The estimated EPS forecast for the next fiscal year is $7.57 and is expected to report on February 14th, 2019.
Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
